Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
With a market cap of 217.63B, Novo Nordisk(NVO) trades at $47.37. The stock has a price-to-earnings ratio of 13.33 and currently yields dividends of 2.5%.
On 2025-11-06, Novo Nordisk(NVO) stock moved within a range of $47.04 to $47.66. With shares now at $47.37, the stock is trading +0.7% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 577.55K, compared to an average daily volume of 16.86M.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.
NVO News
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S (NYSE:NVO) is surging amid a potential deal with the Trump administration, which...
Ever wondered if Novo Nordisk is still a bargain or if the market has already priced in its strengths? Here is a breakdown of what has been happening and what t...
Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Elevate Your Investing Str...
Analyst ratings
63%
of 32 ratingsMore NVO News
(RTTNews) - Metsera Inc. (MTSR) released a statement after the Delaware Court of Chancery rejected Pfizer Inc.'s (PFE) request for a temporary restraining order...
New insider activity at Metsera, Inc. ( (MTSR) ) has taken place on November 5, 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...
Pfizer (PFE) has matched Novo Nordisk’s (NVO) offer to buy weight-loss drug start-up Metsera (MTSR) for up to $10B, Financial Times’ Oliver Barnes, James Fontan...
Pfizer (PFE) issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to...
Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, has a $10 billion offer pending for Metsera. mads claus rasmussen...
In a letter to the lawyers of Pfizer (PFE) and Novo Nordisk (NVO), Federal Trade Commission director Daniel Guarnera said Novo Nordisk’s latest takeover offer f...
Novo Nordisk CFO On Metsera, Hims And Lilly, And Why 'Hyper Growth' Has Stalled 11/05/2025 Novo Nordisk stock skidded early Wednesday after the Wegovy and Ozem...
